SI-BONE, Inc.
HealthcareNASDAQ:SIBN · NASDAQ Global Market
+$0.28 today
Vol 0.22M · Avg 0.69M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-10.7%
avg -99.9%
ROIC
-10.4%
avg -35.3%
ROA
-7.9%
avg -33.5%
Analysis
ROA is currently the strongest return metric at -7.9% versus its period average of -33.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Laura A. Francis | Chief Executive Officer & Director | $1.41M | — | 59 | $37,947.00 | 0.09% |
Anthony J. Recupero | Advisor | $900,418.00 | — | 66 | $262,376.00 | 0.59% |
Anshul Maheshwari | COO & CFO | $814,039.00 | — | 46 | $260,671.00 | 0.59% |
Michael A. Pisetsky | Chief Business & Legal Affairs Officer, Secretary and General Counsel | $756,146.00 | — | 48 | $37,947.00 | 0.09% |
Jeffrey W. Dunn | Executive Chairman | $90,000.00 | — | 70 | $16,057.00 | 0.04% |
Daniel Joseph Cher | Senior Vice President of Clinical, Regulatory Affairs & Quality | — | — | 61 | $25,857.00 | 0.06% |
Scott A. Yerby | Senior Vice President of Engineering & Chief Technology Officer | — | — | 58 | $37,947.00 | 0.09% |
W. Carlton Reckling | Chief Medical Officer & Vice President of Medical Affairs | — | — | 63 | $49,170.00 | 0.11% |
Jeffrey D. Zigler | Senior Vice President of Market Access & Reimbursement | — | — | — | $16,057.00 | 0.04% |
Nikolas F. Kerr | Chief Commercial Officer | — | — | 54 | — | — |
Saqib Iqbal | Vice President of Financial Planning & Analysis and Investor Relations | — | — | — | — | — |
Ian Bailey | Vice President of Product & Marketing | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
103
$7.53M
Net Sentiment
$7.53M
Net selling
Most Active
Maheshwari Anshul
26 transactions
1–10 of 103
Analysis
Insiders reported 0 buys worth $0.00 and 103 sells worth $7.53M over the last 12 months. That adds up to net selling of $7.53M. Maheshwari Anshul was the most active insider with 26 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | -4.9% | +17.4% (14yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -4.9% over three years. Forward estimates point to Revenue at +17.4% (14yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Butterfly Network, Inc.
NYSE:BFLY
$1.45B
InnovAge Holding Corp.
NASDAQ:INNV
$1.24B
Avanos Medical, Inc.
NYSE:AVNS
$1.17B
Varex Imaging Corporation
NASDAQ:VREX
$464.78M
Aquestive Therapeutics, Inc.
NASDAQ:AQST
$414.11M
Pacific Biosciences of California, Inc.
NASDAQ:PACB
$406.89M
ClearPoint Neuro, Inc.
NASDAQ:CLPT
$403.06M
AirSculpt Technologies, Inc.
NASDAQ:AIRS
$377.42M
Orthofix Medical Inc.
NASDAQ:OFIX
$376.33M
Anavex Life Sciences Corp.
NASDAQ:AVXL
$231.68M
Who manages SIBN?
SI-BONE, Inc. (SIBN) lists 12 active executives. The top listed executive is Daniel Joseph Cher, Senior Vice President of Clinical, Regulatory Affairs & Quality.
Are SIBN insiders buying or selling?
Recent insider activity shows net selling of $10.92M.
Explore More
Continue the stock analysis
Jump to another research area for this company.